Tvardi Therapeutics Inc (TVRD) Q4 2025 Earnings Call Transcript

Why It Matters

The earnings underscore Teva’s successful pivot to innovative medicines, boosting profitability and leverage and setting a clear path to its 2027 growth and margin objectives.

Key Takeaways

• Revenue $4.5B, 3% YoY growth.
• AUSTEDO sales $618M, up 38%.
• Adjusted EBITDA up 6%; EPS $0.78, +14%.
• Net debt/EBITDA below 3x, aiming 2x by 2027.
• Biosimilars to add $400M revenue by 2027.

Pulse Analysis

Teva’s latest earnings call highlights a decisive turnaround for a company once synonymous with generic volume. After a decade of declining sales, the firm posted $4.5 billion in quarterly revenue, driven primarily by a revitalized innovative pipeline. Strong demand for branded therapies such as AUSTEDO, UZEDY and AJOVY lifted the innovative segment to more than $800 million, delivering a 33% year‑over‑year surge that outpaced the modest 2% rise in generic sales. This growth trajectory aligns with Teva’s strategic focus on high‑margin, specialty products and reflects the positive impact of recent Inflation Reduction Act (IRA) negotiations that secured favorable pricing for AUSTEDO.

The AUSTEDO franchise emerged as the centerpiece of Teva’s growth story, surpassing $600 million in U.S. sales for the first time and prompting an upward revision of full‑year guidance to $2.05‑$2.15 billion. Complementary launches, including the long‑acting injectable UZEDY and migraine preventive AJOVY, posted double‑digit gains, reinforcing the company’s diversified specialty portfolio. In parallel, Teva’s biosimilars pipeline, now ten assets in‑line with six additional launches slated through 2027, is projected to contribute an incremental $400 million, expanding the firm’s presence in a market traditionally dominated by larger biologics players.

Beyond top‑line growth, Teva is executing a $700 million cost‑transformation program that has already delivered roughly half of its 2025 savings target. The initiative, combined with disciplined capital allocation, helped push net debt/EBITDA below the 3× threshold for the first time since 2016, with a 2.8× outlook by year‑end and a 2× goal for 2027. These financial levers, together with a robust late‑stage pipeline—including olanzapine LAI, duvakitug Phase III trials, and anti‑IL‑15 programs—position Teva to sustain mid‑single‑digit revenue CAGR, achieve a 30% operating margin, and generate strong free‑cash‑flow conversion in the coming years.